Long-term tamoxifen treatment: A possible aetiological factor in the development of uterine carcinosarcoma: Two case-reports and review of the literature

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 2015-2020

  Fotiou, Stelios ^a,b   Hatjieleftheriou, George ^a   Kyrousis, Grigoris ^a   Kokka, Fani ^a   Apostolikas, Nikiforos ^a  

^a G Papanicolaou Research Center for Oncology   (Greece)

^b 1st Department of Medical Oncology   (Greece)

Author keywords

Possible aetiological association; Prolonged tamoxifen treatment; Uterine carcinosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CASE REPORT; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; LONG TERM CARE; MUELLERIAN DUCT; PERITONEUM METASTASIS; POLYP; PRIORITY JOURNAL; PROGNOSIS; UTERUS CARCINOMA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOSARCOMA; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; MASTECTOMY; METHOTREXATE; MIXED TUMOR, MULLERIAN; NEOPLASMS, SECOND PRIMARY; OVARIECTOMY; PERITONEAL NEOPLASMS; POLYPS; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 0033883418     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cole MP, Jones CJA and Todd IDM: A new anti-oestrogenic agent in late breast cancer. Br J Cancer 25: 270-5, 1971.
2. Love RR: Tamoxifen prophylaxis in breast cancer. Oncology (Williston Park) 6: 33-43, 1992.
3. Fentimen IS and Powles TJ: Tamoxifen and benign breast problems: Lancet ii: 1070-1077, 1987.
4. Powles TJ, Tillyer CR and and Jones AJ: Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26: 680-684, 1990.
5. Wakeling AE and Bowler J: Biology and mode of action of pure antiestrogens. J Steroid Biochem 30: 141-147, 1988.
6. Cohen I, Beyth Y, Tepper R, Figer A et al: Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: A new entity? Gynecol Oncol 58: 86-91, 1995.
7. Cohen I, Beyth Y, Tepper R, Shapira J et al: Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol 60: 54-58, 1996.
8. Hardell L: Tamoxifen as risk factor for carcinoma of the corpus uteri. Lancet 2: 563, 1988.
9. Fotiou S, Tserkezoglou A, Hadjieleftheriou G, Apostolikas N et al: Tamoxifen associated uterine pathology in breast cancer patients with abnorlnal bleeding. Anticancer Res 18: 625-630, 1998.
10. Major FJ, Blessing JA, Silverberg SG et al: Prognostic factors in early - stage uterine sarcoma: a gynecologic oncology group study. Cancer 71: 1702-1709, 1993.
11. Clement PB and Scully RE: Tumours with mixed epithelial and mesenchymal elements. In: Tumors and tumor like lesions of the uterine corpus and cervix (Clement PB and Young RH, eds). New York, Churchill Livingstone, 1993, pp. 329-339.
12. Sreenan JJ and Hart WR: Carcinosarcomas of the female genital tract. Am J Surg Pathol 19: 666-674, 1995.
13. Chumas JC, Mann WJ and Tseng L: Malignant mixed Mullerian tumor of the endometrium in a young woman with polycystic ovaries. Cancer 52: 1478-1481, 1983.
14. Press MF and Scully RE: Endometrial "sarcomas" complicating ovarian thecoma polycystic ovarian disease and estrogen therapy. Gynecol Oncol 21: 135-154, 1985.
15. Altaras MM, Aviram R, Cohen I et al: Case report. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 49: 255-258, 1993.
16. Clarke MR: Case report. Uterine malignant mixed Mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol Oncol 51: 411-415, 1993.
17. Evans MJ, Langlois NEI, Kitchener HC and Miller ID: Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus? Int J Gynecol Cancer 5: 310-313, 1995.
18. McCluggage WG, McManus DT, Lioe TF and Hill CM: Uterine carcinosarcoma in association with tamoxifen therapy. Br J Obstet Gynecol 104: 748-750, 1997.
19. Seoud MAF, Johnson J and Weed JC: Gynecologic tumors in tamoxifen treated women with breast cancer. Obstet Gynecol 82: 165-169, 1993.
20. Silva EG, Tornos CS and Follen-Mitchell M: Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13: 248-258, 1994.
21. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 47: 827-833, 1994.
22. Stewart HJ and Knight GM: Tamoxifen and the uterus and endometrium (letter) Lancet 1: 375-376, 1989.
23. Bocklage T, Kenneth RL and Belinson JL: Case report. Uterine Mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol 44: 104-109, 1992.
24. Mourits MJE, Hollema H, Willemse PHB et al: Case report. Adenosarcoma of the uterus following tamoxifen treatment for breast cancer. Int J Gynecol Cancer 8: 168-171, 1998.
25. Fornander T, Cedarmark B, Mattsson A et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 21: 117-120, 1989.
26. Van Leeuwen FE, Benraadt J, Coebergh JWW et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994.
27. Fisher B, Constantino JP, Redmond CK et al: Endometrial cancer in tamoxifen - treated breast cancer patients: findings from the NSABP B-14. J Natl Cancer Inst 86: 527-537, 1994.
28. Kedar RP, Bourne TH, Powles TJ et al: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318-1321, 1994.
29. Curtin JP, Silverberg SG, Thigpen JT and Spanos WJ: Corpus: Mesenchymal tumors. In: Gynecologic oncology (Hoskins WJ, Perez CA and Young RC eds.). New York, Lippincott - Raven, 1997, pp 897-918.
30. Anerbach HE, Li Volsi VA and Merino MJ: Malignant mixed mullerian tumors of the uterus: an immunohistochemical study. Int J Gynecol Pathol 7: 123, 1998.
31. Bitterman P, Chun BK and Kurman RJ: The significance of epithelial differentiation in mixed mesodermal tumors of the uterus: a clinicopathological and immunohistochemical study. Am J Surg Pathol 14: 317, 1990.
32. Klein W, Maier T, Geyer H and Pfleiderer A: Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 38: 59-65, 1990.
33. Silverberg SG, Major FJ, Blessing JA et al: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9: 1-19, 1990.
34. Silverberg SG: Leiomyosarcoma of the uterus: a clinicopathologic study. Obstet Gynecol 38: 613, 1971.
35. 3H]hydroxytamoxifen to uterme oestrogen- and antioestrogen-binding sites. Histochem J 21: 52-60, 1989.
36. Magriples U, Naftolin F, Schwartz PE and Carcangiu ML: High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11: 485-490, 1993.
37. Stewart HJ: The Scottish trial on adjuvant tamoxifen in node-negative breast cancer. Natl Cancer Inst Monogr 11: 117-120, 1992.
38. Norris HJ and Taylor HB: Post irradiation sarcomas of the uterus. Obstet Gynecol 26: 689-694, 1965.
39. Petterson F, Fotiou S, Einhorn N and Silfversward C: Cohort study of the long-term effect of irradiation for carcinoma of the uterine cervix. Acta Radiol Oncol 24: 145-151, 1985.
40. Norris HJ and Taylor HB: Mesenchymal tumors of the uterus II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 28: 57-63, 1966.
41. Norris HJ and Taylor HB: Mesenchymal tumors of the uterus III. A clinical and pathologic study of 31 carcinosarcomas. Cancer 19: 1459-1465, 1966.
42. Macasaet MA, Waxman M, Fruchter RG et al: Prognostic factors in malignant mixed mesodermal (Mullerian) tumors of the uterus. Gynecol Oncol 20: 32-42, 1985.